



XANAMEM CLINICAL ADVISORY BOARD CONFERENCE CALL

- Investor conference call with the Xanamem™ Clinical Advisory Board
- Conference call on Tuesday 14th April at 9am AEST
- Shareholders opportunity to speak live to Profs Ritchie and Masters, and CEO Dr Bill Ketelbey
- Profs Ritchie, Masters and Jeff Cummings, global leaders in Alzheimer's R&D, recently appointed to the Xanamem™ Clinical Advisory Board.
- Advisory Board to assist in designing Phase II efficacy and safety study in patients with early and prodromal Alzheimer's disease.
- Input from the Clinical Advisory Board will enable an Investigational New Drug (IND) application to the Food and Drug Administration's (FDA) for a Phase II study of Xanamem™ in the US

Sydney, 13 April 2015: Actinogen Limited (Actinogen Medical, ASX: ACW), will be hosting an investor conference call with two members of its Xanamem™ Clinical Advisory Board, Professor Craig Ritchie and Professor Colin Masters on **Tuesday 14 April 2015 at 9.00am AEST**. The call will be hosted by Actinogen Medical Chief Executive Officer, Dr Bill Ketelbey.

Xanamem™ is being developed as a potential new therapy for Alzheimer's disease, a condition with a multi-billion dollar market potential. The cost of Alzheimer's treatment in the US alone was estimated to be US\$250bn last year by the American Alzheimer's Association.

The drug works by blocking the development of cortisol - the stress hormone - in the hippocampus, the area of the brain most affected by Alzheimer's disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer's disease.

Shareholders will have the opportunity to ask Professors Ritchie and Masters and Dr Ketelbey questions regarding the Company's lead research drug candidate, Xanamem™ and its potential in early Alzheimer's disease and its precursor stage, prodromal Alzheimer's disease or Mild Cognitive Impairment, as well as trends and issues in Alzheimer's diagnosis and treatment.

As previously announced the Advisory Board has particular expertise in the early diagnosis and treatment of Alzheimer's disease and will help Actinogen Medical shape and drive the development of Xanamem™. The first major priority for the Clinical Advisory Board will be to assist Actinogen in designing the optimum Phase II study to best demonstrate the efficacy and safety of Xanamem™ in patients with Alzheimer's disease and prodromal Alzheimer's/Mild Cognitive Impairment.

Actinogen Medical expects to start this Phase II study in early 2016 and for it to run in Australia/New Zealand, Europe and the USA, under an FDA approved Investigational New Drug (IND).

To join the conference call, please dial via the numbers below.

Audio Access Code: 207 273 – please provide this ID when joining the call.

Dial-in details:

Australian Participant Dial-in Numbers:

Toll: +61 2 9007 3187

Toll free: 1800 558 698

International Participant Dial-in Numbers

These numbers are toll-free dial in numbers for each country listed below:

These numbers are toll-free dial-in numbers for each country listed below. For countries not listed below, the Australian Participant Toll number listed above can be dialled. To ask a question, participants will need to dial “*1” (star, 1) on their telephone keypad.

Canada 1855 8811 339

Hong Kong 800 966 806

Japan 0053 116 1281

Singapore 800 101 2785

China 4001 200 659

India 0008 0010 08443

New Zealand 0800 453 055

United States 1855 8811 339

United Kingdom 0800 051 8245

ENDS

Actinogen Medical

Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 [@BillKetelbey](https://twitter.com/BillKetelbey)

About Actinogen Medical

Actinogen Medical is an Australian biotechnology company focused on the treatment of Alzheimer’s disease and prodromal Alzheimers/Mild Cognitive Impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer’s dementia. It is developing a novel drug to treat Alzheimer’s disease and other age-related neurodegenerative diseases. The lead candidate Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques – hallmarks of Alzheimer’s. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results expected in mid-2015. Actinogen Medical plans to initiate a Phase II study in Alzheimer’s and Mild Cognitive Impairment in 2016.

About Xanamem™

Xanamem™ is under development as a potential new therapy for Alzheimer’s disease and prodromal Alzheimers/Mild Cognitive Impairment, conditions with a multi- billion dollar market potential. Xanamem™’s novel mechanism of action sets it apart from existing Alzheimer’s treatments. It works by blocking the production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease. There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death – the hallmarks of Alzheimer’s disease.